The DNA Directed RNA Polymerase pipeline drugs market research report outlays comprehensive information on the DNA Directed RNA Polymerase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the DNA Directed RNA Polymerase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Oncology, Gastrointestinal, and Hematological Disorders which include the indications Tuberculosis, Coronavirus Disease 2019 (COVID-19), Pancreatic Cancer, Solid Tumor, Hepatic Encephalopathy, Irritable Bowel Syndrome, and Sickle Cell Disease. It also reviews key players involved in DNA Directed RNA Polymerase targeted therapeutics development with respective active and dormant or discontinued products.
The DNA Directed RNA Polymerase pipeline targets constitutes close to 48 molecules. Out of which, approximately 37 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 6, 7, 5, 15, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 6 molecule.
DNA Directed RNA Polymerase overview
DNA-directed RNA polymerase (DdRP or RNAP) is an enzyme that transcribes DNA into RNA. It’s an essential part of the transcription of replicating systems in prokaryotic and eukaryotic organisms, as well as cytoplasmic DNA viruses. In eukaryotes, there are three different forms of DNA-directed RNA polymerases transcribing different sets of genes.
For a complete picture of DNA Directed RNA Polymerase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
